Welcome to our dedicated page for NASDAQ news (Ticker: nasdaq), a resource for investors and traders seeking the latest updates and insights on NASDAQ stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NASDAQ's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NASDAQ's position in the market.
Atossa Therapeutics (Nasdaq: ATOS) announced that Chairman & CEO Steven Quay, M.D., Ph.D. will present at the Maxim Growth Summit on October 22–23, 2025 at the Hard Rock Hotel, New York City.
The company invited new and existing investors to attend or request one-on-one meetings to discuss Atossa's clinical programs, development plans, and capital-allocation strategy focused on preparing data packages for potential regulatory submissions and commercialization.
Investors are directed to the Atossa investor website for presentations, SEC filings, FAQs, and meeting requests.
Atossa (NASDAQ: ATOS) appointed Mark Daniel, CPA, as Chief Financial Officer effective Oct 14, 2025 to lead finance, systems, and capital strategy as the company prepares for commercial launch of (Z)-endoxifen.
Mr. Daniel brings >25 years of life‑sciences finance experience, including weekly revenue forecasting with commercial teams, management of operating budgets >$200M, implementation and certification of SOX controls, programs delivering >$50M in cost savings, stewardship of a $400M cash and investments portfolio, and participation in nearly $1B of equity, convertible debt, and credit transactions.
Atossa Therapeutics (NASDAQ: ATOS) announced expansion of its global intellectual-property strategy for Z-endoxifen, including issuance of an Israeli patent (No. 304863) granted on July 2, 2025 and a Certificate of Patent Renewal confirming fee payment and active status.
The Israeli claims cover oral delayed-release enteric dosage forms with at least 90% Z-endoxifen, optional impurity limits (<2%), defined gastric/intestinal release characteristics, dose strengths (e.g., 1–4 mg and 8 mg), pharmacokinetic targets, and manufacturing methods that enrich the Z-isomer via crystallization and solvent control.
Stealth BioTherapeutics (NASDAQ) launched the Mito Assist™ Patient Support Program and named AnovoRx as exclusive U.S. specialty pharmacy distributor for FORZINITY™ (elamipretide) injection. FORZINITY received FDA accelerated approval on September 19, 2025 as the first treatment for Barth syndrome to improve muscle strength in patients ≥30 kg. Mito Assist provides co-pay assistance, patient assistance for uninsured or underinsured individuals, at-home subcutaneous injection training, and dedicated case management via AnovoRx. Current Expanded Access Program patients meeting the weight requirement will be contacted for transition. Commercial availability through AnovoRx is anticipated by December 2025, pending distribution readiness and payer coverage activation.
The Joint Corp (NASDAQ: JYNT) was named to the Franchise Times Top 400 for 2025, ranking 139 and moving up 11 spots year-over-year. This marks the company's sixth year inside the top 200 franchised systems by global, systemwide sales. The company highlighted growth across the health and medical and personal services sectors and emphasized its retail clinic model offering no-appointment, no-insurance-hassle, affordable chiropractic care with extended hours. Leadership said the ranking validates the brand and supports continued expansion to increase access to routine chiropractic services nationwide.
Atossa Therapeutics (NASDAQ: ATOS) amended its Phase 2 EVANGELINE study of (Z)-endoxifen in premenopausal ER+/HER2– early breast cancer to a single-arm, open-label, non-registrational design. The amendment reduces planned enrollment from 214 to 40–65 patients, implements a Cohort A two-stage futility rule using Week-4 Ki-67 ≤10% for earlier go/no-go decisions, and retains unchanged patient-safety data collection and DSMC oversight. Run-in data showed a Week-4 Ki-67 ≤10% rate of 86%. The company says the change aims to cut future study costs, accelerate objective readouts, and prioritize NDA-enabling activities in 2026.
Core Natural Resources (NYSE: CNR) reported Q2 2025 financial results, highlighting $220.2 million in operating cash flow and $131.1 million in free cash flow. The company posted a net loss of $36.6 million ($0.70 per share) and adjusted EBITDA of $144.3 million. Core increased its merger-related annual synergies target to $150-170 million.
Key operational highlights include $1.1 billion in revenues, return of $87.1 million to stockholders through buybacks and dividends, and strong performance in high c.v. thermal coal and Powder River Basin segments. The company maintains $948 million in total liquidity, including $413 million in cash. Core expects to resume longwall production at Leer South by end of October 2025, with anticipated insurance recoveries exceeding $100 million.
Fusion Connect has secured an $85 million term loan from Hark Capital through a NAV-based loan agreement. The funding will be allocated for operating capital, debt reduction, and strategic investments to accelerate growth. The company, specializing in cloud communications services, plans to invest in talent, technology, infrastructure, customer service, and product development.
Fusion Connect differentiates itself by offering a comprehensive suite of communications services with an all-US-based support team, backed by a 100% uptime guarantee. The company focuses on serving mid-market and enterprise organizations, particularly those with multi-location operations.
